EHA 2025 | A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
Eric Deconinck, MD, PhD, CHU Besançon, Besançon, France, discusses the effectiveness of standard chemotherapy as first-line treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the context of emerging CD123-targeted therapies. Dr Deconinck highlights a Phase II protocol to establish a safe combination of chemotherapy, particularly for patients who do not have access to tagraxofusp. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Our study demonstrated that standard chemotherapy could be efficient for treating patients with BPDCN, especially when we do not have access to CD123-targeted therapy. Because CD123-targeted therapy, especially tagraxofusp, is easily accessible and is commercialized in the United States. It was approved in Europe, but it is available only in a few countries, and especially in France, this product is not available...
Our study demonstrated that standard chemotherapy could be efficient for treating patients with BPDCN, especially when we do not have access to CD123-targeted therapy. Because CD123-targeted therapy, especially tagraxofusp, is easily accessible and is commercialized in the United States. It was approved in Europe, but it is available only in a few countries, and especially in France, this product is not available. And that’s why in an attempt to build a reference chemotherapy, we have built a phase two protocol to establish a safe combination of chemotherapy to offer some kind of treatment to the patient. Because BPDCN is a rare disease, but it’s also a disease that affects elderly people. And it’s very difficult and the only treatment that can cure the patient, even with the use of CD123 therapy, is to go to an allotransplantation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
